Serena Lunardi

Serena has more than eight years of biotech experience in leading drug discovery programs and translational research using different therapeutic modalities ranging from small molecule inhibitors and protein degraders to mRNA-based therapeutics. She is very enthusiastic about propelling and integrating the work of talented people to advance new therapeutics.

Throughout her career in biotech, Serena has kicked several projects off the ground and led those with data-driven decisions from early proof-of-concept studies into the drug discovery pipeline. She has also performed translational work to inform clinical development. While at Oryzon Genomics, Serena led the preclinical translational work that was the basis for the clinical research strategy of Iadademstat, an LSD1 inhibitor currently in Phase II clinical trials for AML and SCLC indications.